Citations 0
April 2010

Interferon Neutralizing Antibodies in Multiple SclerosisA New Perspective

Author Affiliations

Author Affiliation: Multiple Sclerosis Center at Texas Neurology and Baylor Institute for Immunology Research, Dallas.


Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Neurol. 2010;67(4):386-387. doi:10.1001/archneurol.2010.31

The significance of antibodies induced by therapeutically administered formulations of recombinant human interferon β (IFN-β) in multiple sclerosis (MS) has been a controversial topic since it was first reported in association with IFN-β-1b in 1993.1 Indeed, all current formulations of IFN-β are immunogenic (but in varying degrees) such that high titers of induced IFN-β neutralizing antibodies (NAb) do in fact neutralize in vitro IFN-β bioactivity. With regard to all currently available IFN-β—despite early, inconclusive, and often opposing studies—review of the world literature on this topic has allowed task forces of the European Federation of Neurological Societies2 and the American Academy of Neurology3 to agree on several important conclusions:

First Page Preview View Large
First page PDF preview
First page PDF preview